null
Mezigdomide Triplet Cuts Progression Risk by 52% in Relapsed MyelomaByAndrea Eleazar, MHSMay 30th 2026
Elrexfio Improves Progression-Free Survival in Multiple Myeloma Phase 3 TrialByQuincy AttobrahApril 30th 2026
Is a Functional Cure for Multiple Myeloma Within Reach?ByDr. Natalia Neparidze,Dr. Prerna Mewawalla,Dr. Ajay ChariApril 24th 2026